A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson s disease
Introduction. On average 40% of all patients suffering from Parkinson’s disease (PD) undergo bouts of depression. It is thought that this is due to a dysfunction in the orbitofrontal and dorsolateral circuits, together with hypometabolism in the orbital, caudate nucleus and frontal dorsolateral tract regions. Aims. The aim of this study is to compare the effectiveness of low doses of fluoxetin with that of low doses of amitriptyline in controlling depression in patients with PD. Patients and methods. The study examined a total of 77 patients (34 females and 43 males), with an average age of 68.2 years, who had been suffering from PD (according to the diagnostic criteria of Calne et al, in stage II of Hoehn and Yahr) for an average of 6.9 years. They were divided randomly into two groups which received fluoxetin (37 patients, dosage: 20-40 mg/day) or amitriptyline (40 patients, dosage: between 25 and 75 mg/day). A basal evaluation and four others (at 3, 6, 9 and 12 months of treatment) were performed, including the STMS (Short test of mental status), the Hamilton scale, and extent of functional disability using the UPDRS. A statistical analysis was performed by comparing the variance of the above-mentioned parameters and the c2 test with Yates correction or the Fisher exact two-tailed test, to evaluate the reasons for dropping out. In both cases a value of p< 0.05 was accepted as significant. Results. 58 patients finished the study. Drop-out because of side effects only took place in the group that received amitriptyline (p< 0.02), which was better than fluoxetin at controlling the depression (p< 0.009, 0.001, 0.002 and 0.00006) at 3, 6, 9 and 12 months, respectively. Conclusions. At an average dosage of 35.2 mg/day, amitriptyline is effective in controlling the depression presented by patients with PD. However, despite the low dosage, the side effects it caused forced 15% of the patients abandon the treatment.
KeywordsAmitriptylineDepressionFluoxetinCategoriesNeurodegeneraciónNeuropsiquiatríaTrastornos del movimiento
FULL TEXT(solo disponible en lengua castellana / Only available in Spanish)
Si ya es un usuario registrado en Neurologia, introduzca sus datos de inicio de sesión.
Rellene los campos para registrarse en Neurologia.com y acceder a todos nuestros artículos de forma gratuita
¿Olvidó su contraseña? Introduzca su correo electrónico y le haremos llegar una nueva
Estimado usuario de Revista de Neurología,
Debido a la reciente fusión por absorción de VIGUERA EDITORES, S.L.U., la entidad gestora de las publicaciones de Viguera Editores, entre ellas, Revista de Neurología, por EVIDENZE HEALTH ESPAÑA, S.L.U., una de las sociedades también pertenecientes al Grupo Evidenze, y con la finalidad de que Usted pueda seguir disfrutando de los contenidos y distintos boletines a los que está suscrito en la página web de neurologia.com, es imprescindible que revise la nueva política de privacidad y nos confirme la autorización de la cesión de sus datos.
Lamentamos informarle que en caso de no disponer de su consentimiento, a partir del día 28 de octubre no podrá acceder a la web de neurologia.com
Para dar su consentimiento a seguir recibiendo la revista y los boletines de neurologia.com vía correo electrónico y confirmar la aceptación de la nueva política de privacidad, así como la cesión de sus datos a Evidenze Health España S.L.U., el resto de las entidades del Grupo Evidenze y sus partners y colaboradores comerciales, incluyendo la posibilidad de llevar a cabo transferencias internacionales a colaboradores extranjeros, pulse en el siguiente enlace:
OPEN ACCESS
